Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – HC Wainwright raised their Q3 2026 earnings estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Monday, August 17th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.20) per share for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.89) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.52) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $1.83 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01.

Several other research firms have also recently issued reports on NMRA. Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Royal Bank Of Canada decreased their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Needham & Company LLC cut their price objective on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Wall Street Zen upgraded shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Mizuho decreased their target price on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Stock Up 7.9%

NMRA stock opened at $1.64 on Wednesday. Neumora Therapeutics has a one year low of $0.83 and a one year high of $3.65. The firm has a market cap of $303.86 million, a PE ratio of -1.33 and a beta of 2.75. The firm’s 50 day moving average price is $1.61 and its 200-day moving average price is $2.11. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds have recently bought and sold shares of NMRA. Invesco Ltd. grew its position in shares of Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after buying an additional 8,383 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Neumora Therapeutics during the fourth quarter worth approximately $27,000. HBK Sorce Advisory LLC acquired a new stake in Neumora Therapeutics in the second quarter valued at approximately $26,000. Virtu Financial LLC acquired a new stake in Neumora Therapeutics in the third quarter valued at approximately $31,000. Finally, Barclays PLC lifted its stake in Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock worth $55,000 after acquiring an additional 20,683 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Trending Headlines about Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from a loss of $1.29 and increased its FY2027 forecast to a loss of $0.68 from $1.25. The revisions suggest the analyst expects Neumora’s losses to narrow faster than previously projected.
• Positive Sentiment: Longer-term estimates also improved materially: FY2028 EPS was raised to a loss of $0.52 from $1.10, FY2029 was upgraded to projected profit of $0.20 from a loss of $0.26, and FY2030 was increased to $1.83 from $1.51. These changes strengthen the potential profitability narrative for the biotechnology company.
• Positive Sentiment: Near-term quarterly forecasts were raised as well. HC Wainwright lifted its Q3 2026 EPS estimate to a loss of $0.20 from $0.32 and its Q4 2026 estimate to a loss of $0.16 from $0.30, indicating expectations for improved operating performance.
• Neutral Sentiment: HC Wainwright’s projections still show Neumora reporting losses through FY2028, while the company’s current-year consensus estimate remains a loss of $0.93 per share. Investors therefore remain dependent on clinical progress, funding, and execution before projected profitability is achieved.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.